Skip to main content

Liraglutide vs Semaglutide

Both Liraglutide and Semaglutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Liraglutide

Evidence A+

Liraglutide (Saxenda / Victoza)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

View full Liraglutide profile →

Semaglutide

Evidence A+

Semaglutide (Ozempic / Wegovy)

A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.

View full Semaglutide profile →

Side-by-Side

AttributeLiraglutideSemaglutide
Evidence GradeA+A+
FDA StatusFDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza)FDA-approved for weight management and type 2 diabetes
Typical Dose0.6–3.0 mg daily (subcutaneous)0.25–2.4 mg weekly (subcutaneous injection)
Clinics Indexed5402,285
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Liraglutide

  • Weight loss
  • Appetite suppression
  • Glycemic control

Key reported benefits — Semaglutide

  • Significant weight loss
  • Appetite suppression
  • Blood sugar control
  • Cardiovascular benefit

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons